cabozantinib

Elana Gotkine FRIDAY, June 9, 2023 (HealthDay News) -- For patients with locally advanced or metastatic renal cell carcinoma with disease progression on or after immune checkpoint inhibitor…

Elana Gotkine THURSDAY, May 11, 2023 (HealthDay News) -- Cabozantinib plus nivolumab and ipilimumab yields significantly longer progression-free survival than treatment with cabozantinib plus nivolumab…

For previously treated patients with locally advanced or metastatic castration-resistant prostate cancer (CRPC), cabozantinib (Cabometyx) plus atezolizumab…

Treatment with cabozantinib (Cabometyx) significantly improved progression-free survival (PFS) in patients with radioactive iodine (RAI)-refractory differentiated thyroid cancer, an…